Form 4: Alignment Healthcare CMO Sells Shares

Alignment Healthcare's Chief Medical Officer, Hyong Kim, sold 18,600 shares of common stock for approximately $15.03 per share under a pre-arranged trading plan.

Summary

• Chief Medical Officer Hyong Kim of Alignment Healthcare, Inc. (ALHC) sold 18,600 shares of common stock.
• The transaction occurred on August 13, 2025, at a weighted-average price of $15.0327 per share.
• Shares were sold in multiple transactions within a price range of $15.00 to $15.09 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on March 14, 2025.
• Following this transaction, Hyong Kim beneficially owns 472,167 shares of Alignment Healthcare common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the execution under a pre-planned 10b5-1 program mitigates any negative signal, suggesting a routine financial planning event rather than a lack of confidence in the company's future.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled sale for personal financial planning rather than a reaction to recent negative company developments.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived by the market as a slight reduction in confidence, though this is largely mitigated by the existence of a 10b5-1 plan.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception associated with insider selling.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report is specific to Alignment Healthcare, Inc. and its Chief Medical Officer, and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may observe the insider sale, but the pre-planned nature via a 10b5-1 plan should alleviate concerns about its implications for the company's fundamental performance.

Key Dates

Recommendation

This Form 4 filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan. Such transactions are typically for personal financial management and do not usually indicate a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this information. Investors should consider broader company performance and market conditions.

Keywords

Alignment Healthcare, ALHC, insider trading, Form 4, stock sale, Hyong Kim, Chief Medical Officer, 10b5-1 plan, beneficial ownership